RFA plus lyso-thermosensitive liposomal doxorubicin: In search of the optimal approach to cure intermediate-size hepatocellular carcinoma

Riccardo Lencioni, Dania Cioni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

When heated during a radiofrequency ablation (RFA) procedure to ≥40�C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95% CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalHepatic Oncology
Volume3
Issue number3
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Survival
liposomal doxorubicin
Pharmaceutical Preparations

Keywords

  • hepatocellular carcinoma
  • lyso-thermosensitive liposomal doxorubicin
  • radiofrequency ablation

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Cite this

RFA plus lyso-thermosensitive liposomal doxorubicin : In search of the optimal approach to cure intermediate-size hepatocellular carcinoma. / Lencioni, Riccardo; Cioni, Dania.

In: Hepatic Oncology, Vol. 3, No. 3, 01.08.2016, p. 193-200.

Research output: Contribution to journalArticle

@article{14978fcfbbd34daf954c42c8aa531a3c,
title = "RFA plus lyso-thermosensitive liposomal doxorubicin: In search of the optimal approach to cure intermediate-size hepatocellular carcinoma",
abstract = "When heated during a radiofrequency ablation (RFA) procedure to ≥40{\"i}¿½C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95{\%} CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.",
keywords = "hepatocellular carcinoma, lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation",
author = "Riccardo Lencioni and Dania Cioni",
year = "2016",
month = "8",
day = "1",
doi = "10.2217/hep-2016-0005",
language = "English (US)",
volume = "3",
pages = "193--200",
journal = "Hepatic Oncology",
issn = "2045-0923",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - RFA plus lyso-thermosensitive liposomal doxorubicin

T2 - In search of the optimal approach to cure intermediate-size hepatocellular carcinoma

AU - Lencioni, Riccardo

AU - Cioni, Dania

PY - 2016/8/1

Y1 - 2016/8/1

N2 - When heated during a radiofrequency ablation (RFA) procedure to ≥40�C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95% CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.

AB - When heated during a radiofrequency ablation (RFA) procedure to ≥40�C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95% CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.

KW - hepatocellular carcinoma

KW - lyso-thermosensitive liposomal doxorubicin

KW - radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=85024104826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024104826&partnerID=8YFLogxK

U2 - 10.2217/hep-2016-0005

DO - 10.2217/hep-2016-0005

M3 - Article

AN - SCOPUS:85024104826

VL - 3

SP - 193

EP - 200

JO - Hepatic Oncology

JF - Hepatic Oncology

SN - 2045-0923

IS - 3

ER -